| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/14/2005 | CA2551227A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 07/14/2005 | CA2550727A1 Treatment of coronary or peripheral ischemia |
| 07/14/2005 | CA2548357A1 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2546147A1 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 07/14/2005 | CA2545324A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 07/13/2005 | EP1553099A1 A riboflavin derivative and its manufacture and uses |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore |
| 07/13/2005 | EP1553096A1 Pyrazole compounds |
| 07/13/2005 | EP1553085A1 Cyclic amine derivatives and their use as drugs |
| 07/13/2005 | EP1552846A2 Use of heparinases to decrease inflammatory responses |
| 07/13/2005 | EP1552834A1 Neurotrophic factor production promoter |
| 07/13/2005 | EP1552830A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 07/13/2005 | EP1552828A1 Thrombopoetin receptor activator and process for producing the same |
| 07/13/2005 | EP1552745A1 Therapeutic combinations of venous dilators and arterial dilators |
| 07/13/2005 | EP1551972A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 07/13/2005 | EP1551872A2 G-protein coupled receptors |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551860A1 Glucocorticoid receptor ligands for the treatment of metabolic disorders |
| 07/13/2005 | EP1551857A2 A robust, inducible cardiac preferred expression system for transgenesis |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551834A1 Substituted quinazolinone compounds |
| 07/13/2005 | EP1551822A2 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 07/13/2005 | EP1551794A1 Ureido-substituted aniline compounds useful as serine protease inhibitors |
| 07/13/2005 | EP1551793A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 07/13/2005 | EP1551792A1 Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments |
| 07/13/2005 | EP1551791A1 Novel salt forms of poorly soluble probucol esters and ethers |
| 07/13/2005 | EP1551763A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |
| 07/13/2005 | EP1551452A1 Compositions and methods for therapeutic treatment |
| 07/13/2005 | EP1551440A2 Uses of human zven proteins and polynucleotides |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551413A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551398A1 Pyrazolopyridines and methods of making and using the same |
| 07/13/2005 | EP1551397A2 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 07/13/2005 | EP1551379A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 07/13/2005 | EP1551369A2 Combination therapy for treatment of fibrotic disorders |
| 07/13/2005 | EP1551356A2 Pravastatin pharmaceutical formulations and methods of their use |
| 07/13/2005 | EP1551334A2 Medical device for intra-lumenal delivery of pharmaceutical agents |
| 07/13/2005 | EP1551330A1 Improvements in delivery technology |
| 07/13/2005 | EP1207860A4 Controlled release pellet formulation |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1144364B1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/13/2005 | EP1119363B1 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 07/13/2005 | EP1113795B1 Tryptophanyl esters and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/13/2005 | EP1001976B1 Peptides having potassium channel opener activity |
| 07/13/2005 | CN1639343A Method for detection of leptin receptor ligands |
| 07/13/2005 | CN1639317A Probiotic lactobacillus salivarius strains |
| 07/13/2005 | CN1639195A Selective targeting of tumor vasculature using antibody molecules |
| 07/13/2005 | CN1639190A Transmembrane NFAT inhibitory peptide |
| 07/13/2005 | CN1639188A Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 07/13/2005 | CN1639186A Inhibitors of kallikrein |
| 07/13/2005 | CN1639167A Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity |
| 07/13/2005 | CN1639162A Pyrido(2, 1-a)isoquinoline derivatives as DPP-IV inhibitors |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639158A Thiazole derivatives as NPY receptor antagonists |
| 07/13/2005 | CN1639154A Pyranones useful as ATM inhibitors |
| 07/13/2005 | CN1639150A 异喹啉衍生物 Isoquinoline derivatives |
| 07/13/2005 | CN1639139A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639126A Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639121A 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 07/13/2005 | CN1639120A Indolamid derivatives which possess glycogenphosphorylase inhibitory activity |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1639115A Semicarbazide derivatives and their use as antithrombotics |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 07/13/2005 | CN1638801A Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638792A FGFR agonists |
| 07/13/2005 | CN1638790A Compositions and methods for modulating connexin hemichannels |
| 07/13/2005 | CN1638777A Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 07/13/2005 | CN1638775A Nitric oxide donors for treatment of disease and injury |
| 07/13/2005 | CN1638773A Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient |
| 07/13/2005 | CN1638768A Thiazole and oxazole derivatives that modulate PPAR activity |
| 07/13/2005 | CN1638762A Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638755A Body temperature elevating agents |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638736A Composition and methods for treatment of hyperplasia |
| 07/13/2005 | CN1638650A Composition improving age-related physiological deficits and increasing longevity |
| 07/13/2005 | CN1637019A Vascular adhesion molecules and modulation of their function |
| 07/13/2005 | CN1637010A Extraction and application of paeonol amygdaloside |
| 07/13/2005 | CN1636996A Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| 07/13/2005 | CN1636994A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby |
| 07/13/2005 | CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |
| 07/13/2005 | CN1636980A 二肽腈组织蛋白酶k抑制剂 Dipeptide nitrile cathepsin inhibitors k |
| 07/13/2005 | CN1636597A Compounds for the treatment of female sexual dysfunction |
| 07/13/2005 | CN1636594A Angiostatin and use of the same for inhibition of angiogenesis |
| 07/13/2005 | CN1636590A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 07/13/2005 | CN1636587A Chinese medicine composition for treating cardiac and cerebral vascular diseases and its prepn process |
| 07/13/2005 | CN1636581A Safflower medicine composition and its prepn process and use |